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PROGRAMME
A. PLATFORM PRESENTATIONS
1. Tumour Characteristics of False Negative Imprint 
Cytology In Patients Undergoing Sentinel Lymph Node 
Biopsy.  
AS McCoubrey, E Murray, I Cameron, S Dace.
Altnagelvin Area Hospital, Londonderry, BT47 6SB
Introduction:  Sentinel  Lymph  Node  Biopsy  (SLNB)  is 
set to become the standard of care for axillary staging in 
breast cancer. The aim of this study is to evaluate the tumour 
characteristics associated with false negative intraoperative 
imprint cytology.
Methods: Data was recorded prospectively for 105 consecutive 
patients with clinically node negative breast cancer. All had 
excision of the breast tumour and SLNB followed by axillary 
node clearance. Intra-operative imprint cytology was carried 
out in conjunction with post-operative haematoxylin & eosin 
(H&E) staining and immunohistochemistry (IHC). 
Results: Forty-three patients (41%) had a positive sentinel 
node  diagnosed.  Nine  cases  were  negative  using  imprint 
cytology. Of those 9 cases, 5 had micrometastases on H&E 
or IHC. Therefore there were 4 “true” false negative cases 
(9%). Of those cases that were “true” false negatives, the 
mean invasive cancer size was 27mm (8-60mm). Fifty percent 
of the tumours contained lobular elements.  Median tumour 
grade was 2. All of the tumours were oestrogen receptor (ER) 
positive and 25% were HER-2 positive. Of the 34 remaining 
cases that were SLNB positive, the mean invasive cancer size 
was 32mm (12-70mm). Twenty-six percent of the tumours 
contained lobular elements. Median tumour grade was 2. 
Eighty-five percent of the tumours were ER positive and 9% 
were HER-2 positive.
Conclusion: The use of imprint cytology accurately identifies 
metastatic  spread  in  the  majority  of  patients  undergoing 
SLNB. Although the numbers in this study are small, there 
are no obvious tumour characteristics associated with false 
negative imprint cytology in patients having SLNB.
2. Effect of ingestion of food on the inhibition of DPPIV 
activity by oral metformin in Type 2 diabetes.  
Cuthbertson J1, Patterson S2, O`Harte FPM2, Bell PM1  
1  Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, 
Belfast. 
2  School of Biomedical Sciences, University of Ulster, Coleraine
Introduction: The incretin hormones glucagon-like peptide-1 
(GLP-1) and glucose-dependent insulinotropic polypeptide 
(GIP)  constitute  the  enteroinsular  axis  which  promotes 
postprandial  insulin  secretion.  The  therapeutic  potential 
of  these  hormones  in  diabetes  is  limited  by  their  rapid 
inactivation  by  the  enzyme  dipeptidylpeptidase-IV  (DPP-
IV). Here we investigated the acute effects of metformin in 
the presence and absence of food on DPP-IV activity in Type 
2 diabetes.
Methods: Ten subjects with Type 2 diabetes (6 male/4 female, 
age 65.8±15.8 years (mean ± SEM), body mass index 30.0± 
7.5kg/m2, HbA1c 6.3±1.2%) received metformin 1g orally 
or placebo together with a standard mixed meal (SMM) in a 
random crossover design. Six subjects reattended fasting and 
received metformin 1g without a SMM.
Results: Following SMM (n=10), DPP IV activity was not 
suppressed by metformin compared with placebo (area under 
curve AUC0-4h 1574±4 and 1581±8 µmol/min respectively). No 
differences were observed in plasma glucose, insulin and total 
GLP-1. After fasting (n=6), DPP IV activity was suppressed 
(P<0.02) when compared to those given metformin with a 
SMM (AUC0-4h 1494±9 vs. 1578±4 µmol/min). Metformin 
plasma levels were significantly higher (P<0.03) after fasting 
than SMM (AUC0-4h 457±55 vs. 350±66 mcg/ml). 
Conclusion: Metformin inhibits DPP IV activity in patients 
with Type 2 diabetes in the fasting state but not when taken 
with a standard mixed meal. Metformin plasma concentrations 
are lower if taken with food. Metformin may have potential 
for combination therapy with incretin hormones.
3. Prosthetic stent-graft infection following endovascular 
abdominal aortic aneurysm repair 
Muhammad A Sharif1, Bernard Lee1, Luk L Lau1,2 Peter K 
Ellis2, Anton J Collins2, Paul H Blair2, Chee V Soong1. 
1.  Department of Vascular and Endovascular Surgery, Belfast City Hospital, 
Lisburn Road, Belfast, BT9 7AB, Northern Ireland, United Kingdom.
2.  Department of Vascular Surgery, Royal Victoria Hospital, Grosvenor 
Road, Belfast, BT7 12 AB, Northern Ireland, United Kingdom. 
Objective:  The  purpose  of  this  report  is  to  discuss  the © The Ulster Medical Society, 2008.
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incidence, diagnosis and management of stent-graft infections 
following EVAR1. 
Methods: Data were collected from the hospital database 
and  medical  case  notes  for  all  patients  with  infected 
endografts following elective or emergency EVAR for AAA 
over the last eight years in two university teaching hospitals 
in  Northern  Ireland. The  data  included  the  patient’s  age, 
gender,  presentation  of  sepsis,  treatment  offered  and  the 
ultimate outcome. The diagnosis of graft related sepsis was 
established  by  a  combination  of  investigations  including 
inflammatory markers, labelled white cell scan, Computerized 
Tomography  (CT)  scan,  microbiology  cultures  and  post 
mortem examination. 
Results:  Out  of  a  total  of  509  patients,  including  433 
elective repairs and 76 emergency endografts for ruptured 
AAA, six suffered graft related septic complications. Two 
patients presented with left psoas abscess and were treated 
successfully with extra-anatomical bypass and removal of 
the  infected  stent-graft. A  further  two  patients  presented 
with infected graft without other evidence of intra-abdominal 
sepsis:  one  underwent  successful  removal  of  the  infected 
prosthesis with extra-anatomical bypass while the other was 
treated conservatively and died of progressively worsening 
sepsis. The fifth patient presented with unexplained fever and 
died suddenly, with a post-mortem diagnosis of aorto-enteric 
fistula and ruptured aneurysm. The last patient presented with 
an aorto-enteric fistula, was treated conservatively in view of 
concurrent myelodysplasia, and died of possible aneurysm 
rupture. 
Conclusion:  This  report  is  to  emphasize  the  need  for 
continued  awareness  of  potential  graft-related  septic 
complications in patients undergoing endovascular repair of 
AAA. Attention to detail with regard to sterility and antibiotic 
prophylaxis, during stent-grafting and during any secondary 
interventions, is vital in reducing the risk of infection. In 
addition, early recognition and prompt treatment are essential 
for a successful outcome. 
1   Sharif MA, Lau LL, Lee B, Ellis PK, Blair PH, Soong CV . Prosthetic 
stent-graft infection following endovascular abdominal aortic aneurysm 
repair. J Vasc Surg 2007;46:442-448. 
4. Patients with Primary (Idiopathic) Achalasia Have 
Circulating Peripheral Blood Mononuclear Immune 
Cells That Are Hyper- Reactive To the Herpes- Simplex 
-1 Virus 
KW Lau1, C McCaughey2, PV Coyle2, LJ Murray1, BT 
Johnston3
1  Centre  for  Clinical  and  Population  Sciences,  Queens  University  of 
Belfast,
2  Regional Virus Laboratory, 
3  Department of Gastroenterology, Royal Victoria Hospital, Belfast, United 
Kingdom 
Introduction: Achalasia is the best characterized oesophageal 
motor disorder but the aetiology is unknown. The pathology 
seen  in  achalasia  consists  of  a  decrease  in  nitric  oxide- 
producing neurones and the presence of an activated T-cell 
inflammatory  infiltrate  in  the  myenteric  plexus1.  Certain 
Human Leucocyte Antigen (HLA) class II alleles are also more 
prevalent in patients with primary achalasia1. These factors 
suggest that an autoimmune mechanism may be involved in 
the pathogenesis of primary achalasia. The stimulus initiating 
this is unknown but could involve the Herpes simplex -1 virus 
(HSV -1). A previous study has demonstrated the existence 
of oesophageal mononuclear immune cells reactive to HSV 
-1 antigens in an in- vitro setting2. 
Aims  &  Methods: The  aim  of  this  study  is  to  test  the 
hypothesis  that  circulating  peripheral  blood  mononuclear 
cells in patients with primary achalasia may be reactive to 
HSV- 1. Whole blood culture experiments were conducted 
with heparinised peripheral venous blood obtained from 151 
patients with primary achalasia and 118 healthy controls. 
Whole  blood  was  cultured  in  the  presence  of  ultraviolet 
inactivated HSV – 1 (multiplicity of infection of 1 TCID50 
/ lymphocyte) or conditioned cell culture media. Reactivity 
of  mononuclear  cells  to  viral  antigens  was  quantified  by 
measuring expression of the cytokine gene interferon – gamma 
using Taqman® Real Time Polymerase Chain Reaction. Data 
are expressed as cytokine fold change corresponding to ratio 
of interferon – γ messenger RNA copies produced in antigen 
stimulated versus unstimulated cells. Interferon- γ fold change 
was compared between cases and controls using the unpaired 
student’s– t test after log transformation and expressed as 
median (interquartile range). 
Results: The interferon- γ fold change was higher in cases 
61.33 (20.54 – 217.00) than controls 49.67 (10.05 – 157.05). 
Mean fold change difference between cases and controls was 
1.66 times (95% confidence interval 1.17 – 2.34, p = 0.02). 
Conclusion:  The  results  of  this  study  indicate  that 
mononuclear immune cells hyper- reactive to HSV- 1 are 
present  in  the  peripheral  blood  of  patients  with  primary 
achalasia and may contribute to the pathological changes 
observed in the myenteric plexus. 
1   Park W, Vaezi MF. Etiology and pathogenesis of achalasia: the current 
understanding. Am J Gastroenterol 2005;100:1404-14.
2   Castagliuolo I, Brun P, Costantini M, Rizzetto C, Palu G, Costantino M, 
Baldan N, Zaninotto G. Esophageal achalasia: is the herpes simplex virus 
really innocent? J Gastrointest Surg 2004;8:24-30.
5. The value of PSA testing in men older than 65 years
David Connollya, Amanda Blackb, Liam J. Murrayb, Anna 
Gavinc, Patrick F Keanea. 
a  Department of Urology, Belfast City Hospital, 
b  Cancer Epidemiology & Prevention Research Group, Centre for Clinical 
and Population Sciences, Queen’s University Belfast, 
c  Northern Ireland Cancer Registry, Queen’s University Belfast.
Introduction: Many men ≥65 years old have histological 
prostate  cancer.  Only  a  small  proportion  may  present 
clinically with the disease and relatively few will die from 
prostate cancer. We assessed baseline PSA levels and the risk 
of clinically detected prostate cancer and prostate specific 
mortality in this population.
Methods: From a regional PSA database, all men aged ≥65 
years old who had their first PSA test between 1994 and 
1998 were identified. These were followed for prostate cancer 
diagnosis and mortality until 2003. The absolute risk and 
hazard ratio for prostate cancer diagnosis and mortality, based © The Ulster Medical Society, 2008.
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on baseline PSA level, were determined.
Results:  36003  men  were  included.  Mean  age  was  74.9 
years  and  mean  follow-up  5.4  years.  2153  (6.0%)  men 
were diagnosed with prostate cancer. 13074 (36.3%) died, 
with prostate cancer the cause of death in 673 men (5.1% 
of deaths). Within age groups, the absolute risk and hazard 
ratio  of  cancer  increased  incrementally  with  PSA  level 
(Table). Prostate-specific mortality remained low (<5/1000 
person years) at all PSA categories <15.0ng/ml. All-cause 
mortality was similar in PSA categories <10.0ng/ml, and 
was much greater than prostate-specific mortality across all 
PSA categories. 
Conclusion:  The  risk  of  prostate  cancer  diagnosis  and 
prostate specific mortality is related to baseline PSA level. 
However, in this age group, death from prostate cancer was 
infrequent compared to other causes, even when baseline 
PSA was markedly elevated (up to 20.0ng/ml). A conservative 
approach to invasive investigation may be appropriate in men 
older than 65 years.
6. A randomised interventional trial of omega-3-
polyunsaturated fatty acids on endothelial function and 
disease activity in systemic lupus erythematosus.  
Stephen A Wright1,2,3, Fiona M O’Prey1, Michelle T 
McHenry2,3, William J Leahey1, Adrian B Devine1, Emeir 
M Duffy2,4, Dennis G Johnston1, Michael B Finch2,3, Gary E 
McVeigh1, Aubrey L Bell2,3.
1   Department  of  Therapeutics  and  Pharmacology,  Queens  University 
Belfast, Northern Ireland, 
2   Lupus Research Group, Queens University Belfast, Northern Ireland, 
3   Department of Rheumatology, Musgrave Park Hospital, Belfast, Northern 
Ireland,  
4  Northern Ireland Centre for Food and Health (NICHE), Department of 
Biomedical Sciences, University of Ulster, Northern Ireland
Objective:  To  determine  the  clinical  effect  of  dietary 
supplementation with low dose omega-3-polyunsaturated fatty 
acids on disease activity and endothelial function in patients 
with systemic lupus erythematosus.
Methods: A  24  week  randomised  double-blind  placebo-
controlled  parallel  trial  of  the  effect  of  3g  of  omega-3-
polyunsaturated  fatty  acids  on  60  patients  with  SLE  was 
performed.   Serial measurements of disease activity using 
the  revised  Systemic  Lupus Activity  Measure  (SLAM-R) 
and British Isles Lupus Assessment Group index of disease 
activity for SLE (BILAG), endothelial function using flow 
mediated dilation of the brachial artery (FMD), oxidative 
stress using platelet 8-isoprostanes and analysis of platelet 
membrane  fatty  acids  were  taken  at  baseline,  12  and  24 
weeks.
Results:  In  the  fish  oil  group  there  was  a  significant 
improvement  at  24  weeks  in  SLAM-R  (from  9.4±3.0  to 
6.3±2.5, p<0.001); in BILAG (from 13.6±6.0 to 6.7±3.8, 
p<0.001);  in  FMD  (from  3.0%  (-0.5-8.2)  to  8.9%  (1.3-
16.9), p<0.001) and in platelet 8-isoprostanes (from 177pg/
mg protein (23 – 387) to 90 pg/mg protein (32 – 182), p = 
0.007).
Conclusions:  Low  dose  dietary  supplementation  with 
omega-3 fish oils in SLE not only has a therapeutic effect 
on disease activity but also improves endothelial function 
and  reduces  oxidative  stress  and  may  therefore  confer 
cardiovascular benefits.
7. The systemic effects of cilostazol on exercise-induced 
lower limb ischaemia-reperfusion in patients with 
peripheral arterial disease. 
ME O’Donnell 1, SA Badger 1, RR Makar 1, J McEneny 2, IS 
Young 2, LL Lau 1, B Lee 1, RJ Hannon 1, CV Soong 1.
Department of Vascular and Endovascular Surgery, Belfast City Hospital 
1 and Department of Medicine, Queen’s University Belfast2, Northern 
Ireland.
Objectives:  The  phosphodiesterase-3  inhibitor  Cilostazol 
improves  walking  distance  in  peripheral  arterial  disease 
Absolute rate of cancer / 1000 person years (Hazard Ratio*)
PSA level 65 - 69 70 - 75 75 - 79 ≥80 Prostate specific mortality† All cause mortality†
0.0-1.99 0.8 (1.0)  1.2 (1.0) 1.5 (1.0) 2.3 (1.0) 0.3 (1.0) 57.7 (1.0)
2.0-3.99 3.2 (3.8) 2.3 (1.9) 2.6 (1.8) 4.4 (1.9) 0.6 (2.3) 61.3 (1.0)
4.0-5.99 7.7 (9.2) 5.7 (4.7) 4.0 (2.7) 5.6 (2.5) 1.1 (3.8) 60.3 (1.0)
6.0-7.99 12.8 (15.3) 10.9 (8.9) 9.8 (6.6) 9.2 (4.0) 1.8 (6.4) 65.0 (1.0)
8.0-9.99 20.1 (23.8) 16.5 (13.4) 10.2 (6.9) 11.2 (5.0) 3.3 (11.8) 64.2 (1.0)
10.0-14.99 22.6 (26.7) 29.1 (23.1) 21.1 (14.0) 15.6 (6.6) 3.9 (13.5) 76.2 (1.1)
15.0-19.99 44.2 (51.3) 37.0 (28.9) 36.3 (23.4) 35.8 (14.6) 8.4 (28.6) 86.6 (1.2)
≥20.0 105.1 
(115.2)
107.0 (79.1) 131.6 (77.2) 115.2 (45.8) 34.0 (112.8) 112.9 (1.5)
No. of cancers 476 580 509 588 673 13074
No. of patients 9933 9884 7978 8154 36003 36003
*0.0 - 1.99 used as reference category, †All men, age-adjusted© The Ulster Medical Society, 2008.
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(PAD) patients through an increase in cyclic AMP levels. The 
study objective was to assess the effects of cilostazol on the 
inflammatory response post-exercise in such patients. 
Methods: PAD patients were prospectively recruited to a 
randomised double-blinded, placebo-controlled trial. Baseline 
clinical data were recorded following medical optimisation. 
Initial and absolute walking distances were measured on a 
validated  treadmill  protocol.  Inflammatory  response  was 
assessed  before  and  30-minutes  post-exercise  by  serum 
lipid  hydroperoxide,  interleukins  6  and  10,  intracellular 
and vascular cell-adhesion-molecules (I-CAM & V-CAM), 
highly-selective C-reactive protein (hsCRP) measurement and 
plasma ascorbate analysis. All tests were at baseline, 6-weeks 
and 6-months. 
Results: 106 PAD patients (72 males) were recruited from 
August  2004  to August  2006  (overall  median  age:  66.5, 
range  37-86).  26  patients  were  diabetic. Treatment  limbs 
were demographically and medically matched. Patients who 
received  cilostazol,  compared  to  placebo,  demonstrated  a 
mean  percentage  improvement  from  baseline  in  absolute 
claudication  distance  (77.2%  vs.  26.6%  at  6  weeks  and 
161.7% vs. 79.0% at 6 months, p<0.05, t-test). There was 
a reduction from baseline lipid hydroperoxide levels in the 
cilostazol group compared to an increase in the placebo group 
before and after exercise (6-weeks: pre-exercise: -11.8% vs. 
+5.8% and post-exercise: -12.3% vs. +13.9%) (6-months: 
pre-exercise -15.5% vs. +12.0% and post-exercise: -9.2% 
vs.  +1.9%)  (p<0.01,  MWU-test).  Cilostazol  significantly 
reduced I-CAM and V-CAM levels at 24-weeks compared 
to  baseline  (p<0.05,  WSR-test).  However,  there  was  no 
difference between groups for interleukins 6 and 10, ascorbate 
or hsCRP levels.
Conclusions:  Cilostazol  is  a  highly  efficacious  treatment 
for improving walking distance in patients with PAD with 
additional  beneficial  effects  on  lower  limb  ischaemia-
reperfusion both before and after walking.
B. POSTER PRESENTATION CASE REPORTS
1. Vasoactive intestinal polypeptide secreting pancreatic 
tumour (VIPoma): long term survival after orthotopic 
liver transplantation.  
Johnston PC1, Ardill JE2, Johnston BM2, Mc Cance DR1, 2
1   Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, 
Belfast, BT12 6BA.
2   Neuroendocrine Tumour Group, Royal Victoria Hospital, Belfast, BT12 
6BA.
A 46 year old male presented in 1981 with a two year history 
of  profuse  watery  diarrhoea,  three  stone  weight  loss  and 
fatigue.  On  examination  he  appeared  gaunt  with  diffuse 
muscle  weakness.  Investigations  revealed  hypokalaemia 
(2.5mmol/L;  NR  3.5-4.5),  achlorhydria  and  a  raised 
vasoactive  intestinal  polypeptide  (VIP)  (1500ng/L;  NR 
0-100).  Abdominal CT showed a 5 cm pancreatic mass but 
with no focal liver pathology. A distal pancreatectomy was 
performed.  Histology  confirmed  an  islet  cell  carcinoma 
(VIPoma).
His  symptoms  recurred  one  year  post  surgery,  at  which 
time  liver  metastases  were  demonstrated  radiologically. 
He  responded  initially  to  three  courses  of  Streptozotocin 
but  ultimately  developed  resistance.  For  fifteen  years  his 
symptoms were controlled by octreotide injections, initially 
Sandostatin (subcutaneously) and later Sandostatin LAR. The 
patient also underwent hepatic chemoembolisation. 
By 1997, sixteen years after his initial surgery, treatment 
failure  occurred  with  a  profound  deterioration  clinically 
and  debilitating  diarrhoea.  No  evidence  of  extra  hepatic 
disease was found. After extensive discussion he underwent 
orthotopic liver transplantation which resulted in resolution 
of his symptoms.
Recurrence was noted two years post transplant in the para-
aortic lymph nodes but not in the liver. He remained mildly 
symptomatic with gradual deterioration of his general health 
and died 9 years after liver transplantation.
This case is one of the longest reported (25 years) survivors 
of a VIPoma after initial diagnosis. The case also has several 
notable features including the absence of liver metastases 
at diagnosis and the variety of treatment modalities used 
for symptom control including successful orthotopic liver 
transplantation.
2. Opsoclonus Myoclonus Syndrome as a paraneoplastic 
manifestation of benign ovarian teratoma
AS Fitzpatrick, OM Gray, JP McConville, GV McDonnell
Dept of Neurology, Royal Victoria Hospital, Belfast, BT12 6BA
The Opsoclonus Myoclonus Syndrome (OMS) is characterised 
by  nonrhythmic  involuntary  ocular  oscillations,  axial  and 
segmentary myoclonia and cerebellar ataxia. It can be a post-
infectious, paraneoplastic or idiopathic phenomenon; most 
commonly associated with neuroblastoma in children and 
lung or ovarian malignancies in adults. We report the case 
of a fifteen-year-old girl who presented with subacute onset 
of opsoclonus and myoclonus, ataxia, nausea and vomiting. 
Investigation excluded infection, neuroblastoma, chest and 
breast malignancy but revealed a right-sided benign ovarian 
teratoma. Paraneoplastic and atypical antibodies including 
antibodies to neuronal surface antigens and NMDAR antigens 
were not identified and tumour markers were normal. 
The patient was treated with immunomodulatory treatment 
including  intravenous  steroids  and  immunoglobulin  but 
showed  the  most  improvement  in  response  to  surgical 
removal of the teratoma. We discuss OMS as a paraneoplastic 
manifestation of benign ovarian teratoma. Case reports have 
suggested a variety of neurological paraneoplastic syndromes 
associated with this tumour but its association with OMS has 
not previously been described.  We have video evidence pre 
and post treatment.
3. Macroprolactinomas presenting as nasal polyps: a 
series of three cases. 
PC Johnston, HC Courtney, SJ Hunter, DR McCance
Regional Centre for Diabetes and Endocrinology, Royal Victoria Hospital, 
Belfast, UK
Intranasal  presentations  of  pituitary  tumours  are  rare. 
Management can be difficult and delayed due to their location 
and extension. Macroprolactinomas are uncommon and can © The Ulster Medical Society, 2008.
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often pursue an aggressive clinical course, including invasion 
into the nasopharynx.
We  describe  three  cases  of  prolactinomas  that  initially 
presented  to  the  ENT  Department  as  nasal  polyps.  We 
describe their clinical features and response to treatment. 
Recurrence  of  nasal  polyps  (patient  1)  and  radiological 
evidence of a pituitary mass (patients 2 & 3) prompted testing 
for a prolactinoma. None of the patients had any signs of 
hyperprolactinaemia. All have significant residual tumour at 
follow up, despite prolactin levels approaching the normal 
range on dopaminergic therapy.
Pituitary tumours that invade the nasal cavity are rare and 
clinicians should be aware of their existence. Measurement 
of serum prolactin and immuno-histochemistry for prolactin 
secreting cells in intranasal tumours should be considered if 
there is clinical evidence of hyperprolactinaemia or if there 
is recurrence of the nasal tumour/polyp. This can expedite 
a diagnosis and prevent delay of treatment with dopamine 
agonists. Dopaminergic therapy controls excessive prolactin 
secretion and results in tumour shrinkage in most patients, 
but treatment may be complicated by dopamine resistance, 
extensive tumour necrosis and CSF rhinorrhoea. 
4. Atypical Addison’s Disease. -A case of Familial 
Glucocorticoid Deficiency.
GM Magee, A Thiraviaraj, CH Courtney, SJ Hunter
Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, 
Grosvenor Road, Belfast, BT12 6BA
A  2  yr  old  boy  presented  initially  with  hypoglycaemia 
following a 6h fast prior to an elective surgical procedure.   
Investigations demonstrated low plasma glucose (1.6mmol/l), 
undetectable serum insulin, elevated beta hydroxybutyrate 
(5.2mmol/l) and normal lactate. Plasma amino-acid profile 
was  normal.   The  dorsum  of  his  hands  were  pigmented, 
however  a  synacthen  test  demonstrated  a  normal  cortisol 
response.  Ketotic hypoglycaemia was diagnosed, and his 
parents were given dietary advice.  At age 11, he was referred 
to  medical  genetics  with  poor  coordination,  delayed  fine 
motor skills and a dysmorphic appearance.  Chromosomal 
analysis revealed a normal male karyotype, and no specific 
diagnosis was made.  
He  presented  at  age  18  to  our  unit  with  recurrent 
hypoglycaemia.  A 72h fast was terminated after 10 h as the 
patient was symptomatic with plasma glucose 1.6mmol/l.  A 
synacthen test demonstrated an absent cortisol response and 
elevated ACTH level. Serum electrolytes were normal, adrenal 
autoantibodies were absent and very long chain fatty acids 
were normal.  He was commenced on both glucocorticoid 
and  mineralocorticoid  replacement  and  had  no  further 
hypoglycaemic episodes.
Later  the  patient’s  brother  also  presented  at  age  16  with 
hypoglycaemia  when  he  was  unwell  with  nausea  and 
vomiting.  A diagnosis of primary adrenal insufficiency was 
confirmed - also with normal serum electrolytes and absent 
adrenal autoantibodies.
Further  genetic  analysis  revealed  that  both  brothers  were 
homozygous for the S74I mutation of the MC2 (melanocortin 
2)  receptor  and  a  diagnosis  of  Familial  Glucocorticoid 
Deficiency (FGD) was made. This rare autosomal recessive 
ACTH  insensitivity  syndrome  responds  to  glucocorticoid 
replacement alone. 